ArticleFrontiers in pharmacology2025
Effects of previous steroid treatment on ischemic stroke outcomes: a propensity score-matched hospital analysis.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Comparative Outcomes of Dual vs. Single Antiplatelet Therapy in Acute Ischemic Stroke: A Retrospective Cohort Analysis.Neurology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Stroke is a leading cause of morbidity and mortality worldwide, and its recurrence poses significant challenges to patient management and healthcare systems. This hospital-based retrospective observational study investigated the association between prior exposure to systemic corticosteroids and stroke recurrence within the Saudi Arabian population. Methods: A multicenter retrospective study included acute-subacute adult ischemic stroke patients. Propensity score matching (PSM) was applied to balance baseline characteristics between the steroid and non-steroid groups. The primary outcome was the incidence of stroke recurrence within 365 days of the index stroke. Secondary outcomes included stroke severity and functional independence on admission and discharge, hemorrhagic transformation within 30 days, and mortality rate within 365 days of the index stroke. Results: Out of 925 patients, 85 (9.19%) received steroids. After PSM, the analysis included 254 patients, with 33.46% in the steroid group and 66.54% in the control group. Steroid-exposed patients had significantly lower National Institutes of Health Stroke Scale (NIHSS) scores at both admission (median 5 [interquartile range (IQR): 1-8] vs 6 [IQR: 3-10], Conclusion: The study revealed that steroids were associated with significantly lower stroke severity but higher mRS scores. However, the risk of stroke recurrence was similar between the two groups. Moreover, the use of steroids may increase the risk of complications in stroke patients, such as pneumonia and DVT-PE. Future studies with larger sample sizes and more detailed data on steroid use and stroke outcomes are required. These studies would provide more definitive insights and guide clinical decision-making regarding the use of steroids in stroke management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.